Life Sciences Tools and Services
Company Overview of Myriad RBM, Inc.
Myriad RBM, Inc., a multiplexed immunoassay testing laboratory, provides multi-analyte profile (MAP) technology platform based protein biomarker products and services for research, drug, and diagnostic development projects. Its products and services include HumanMAP services that assist investigators in the discovery, validation, and clinical use of biomarker patterns in biological samples, such as serum or plasma; and RodentMAP services that provide quantitative measurement of various biomarkers to enable new pattern discovery, as well as sensitive safety and efficacy assessments. The company’s products and services also comprise single molecule array technology based Ultrasensitive Immunoa...
3300 Duval Road
Austin, TX 78759
Founded in 2002
Key Executives for Myriad RBM, Inc.
Vice President of IS & Technology
Managing Director of Communications
Vice President of Corporate Development
Compensation as of Fiscal Year 2015.
Myriad RBM, Inc. Key Developments
CDC Plans Sole Source with Rules-Based Medicine for Proteome Evaluation
Jul 19 15
The U.S. Health and Human Services Department's Centers for Disease Control and Prevention, Atlanta, said it intends to enter into a sole source contract (2015-63697SG) with Rules-Based Medicine Inc., Austin, Texas, for the evaluation of proteomes.
Myriad RBM Launches New Immunoassay Services Based on the Ultrasensitive Simoa(TM) Platform
Mar 5 15
Myriad RBM announced the launch of immunoassay services based on the ultrasensitive Simoa™ (single molecule array) platform developed by Quanterix. The Simoa platform enables the accurate measurement of protein biomarkers that were previously difficult or even impossible to detect in blood samples. Initially, Myriad RBM will offer Simoa assay services for the study of inflammatory and autoimmune diseases. The company has manufactured and validated Simoa-based quantitative immunoassays for interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) that are available from its CLIA-certified laboratory in Austin, Texas. Each assay includes carefully designed calibrators and controls to provide multiple measurements of quality, precision and accuracy. Myriad RBM plans to add more Simoa-based immunoassays throughout the year.
Myriad RBM Joins Institut Pasteur in the Global Fight against Tuberculosis
Jan 20 15
Myriad RBM announced that it will assist the Institut Pasteur in a public-private research collaboration to fight the global tuberculosis (TB) epidemic. This research project is funded by the Bill & Melinda Gates Foundation through a grant to the Institut Pasteur. The proof-of-concept study will evaluate patients with latent and active TB infections who are affiliated with the South African Tuberculosis Vaccine Initiative (SATVI) clinical study sites. The goals of this study are to field-test Myriad RBM's TruCulture® system as a point-of-care blood collection and immune response monitoring method and to stratify patients with active and latent tuberculosis. Myriad RBM will supply the study with its revolutionary TruCulture collection systems. Once the blood samples are collected, Myriad RBM and the Institut Pasteur will seek to discover protein biomarkers important in regulating the immune system response using Myriad RBM's proprietary MAP (Multi-Analyte Profiling) platform.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries